FRAMINGHAM, Mass.--Genzyme Molecular Oncology here could earn more than $9 million from a new service and option-to-license agreement it has signed that allows Parke-Davis to use the company's proprietary Sage technology in gene expression studies. Parke-Davis may choose to license Sage for its internal genomics research programs. Initially, the technology will be used in a pharmacogenomics study to analyze gene expression changes in tissue following exposure to potential new drugs.
"SAGE is one of a growing list of genomics technologies Parke-Davis is employing in its drug discovery programs," commented Leonard Post, the company's vice-president of discovery research "We expect SAGE to provide information valuable to many aspects of the discovery and development process."
A high-efficiency, high-throughput method of simultaneously detecting and measuring the expression levels of virtually all genes expressed in a cell at a given time, SAGE can be used in many applications to identify disease-related genes, analyze the effect of drugs on tissues, and provide insight into disease pathways, according to the Genzyme subsidiary. It works by isolating short bits of genetic information from expressed genes that are present in the cell being studied. Known as Sage tags, these short sequences, are linked together for efficient sequencing. The resulting data are then analyzed using Sage software to identify each gene expressed in the cell and the levels at which they are expressed, creating a library that can be used to analyze the differences in gene expression between cells.